BNIP3 |
Breast tumor |
Tumor suppressor |
Inhibits glycolysis and angiogenesis |
Chourasia et al., 2015 |
BNIP3 |
Pancreatic cancer |
Tumor suppressor |
Promotes hypoxia-induced cell death |
Okami et al., 2004 |
BNIP3 |
Colorectal cancer |
Tumor suppressor |
Promotes hypoxia-induced cell death |
Murai et al., 2005; Bacon et al., 2007
|
BNIP3 |
Gastric cancer |
Tumor suppressor |
Promotes hypoxia-induced cell death |
Murai et al., 2005 |
BNIP3L |
Pancreatic ductal adenocarcinoma |
Tumor promoter |
Increases glucose metabolism and antioxidant capacity |
Humpton et al., 2019 |
Ceramide |
Head and neck squamous cell carcinoma, acute myeloid leukemia cells |
Tumor suppressor |
Promotes cell death |
Sentelle et al., 2012; Dany et al., 2016
|
FUNDC1 |
Hepatocellular carcinoma |
Tumor suppressor |
Inhibits inflammation |
Li et al., 2019a |
FUNDC1 |
Laryngeal cancer |
Tumor promoter |
Promotes cell proliferation and survival |
Hui et al., 2019 |
FUNDC1 |
Cervical cancer |
Tumor suppressor |
Promotes apoptosis |
Hou et al., 2017 |
PHB2 |
Cervical/non-small cell lung/colorectal cancer cells |
Tumor suppressor |
Promotes activation of PINK1-PRKN pathway |
Yan et al., 2020 |
PHB2 |
Non-small cell lung carcinoma |
Tumor promoter |
Promotes cell proliferation and migration |
Zhang et al., 2020 |
PINK1 |
Pancreatic ductal adenocarcinoma |
Tumor suppressor |
Inhibits inflammation and antitumor immunity |
Li et al., 2018 |
PRKN |
Pancreatic ductal adenocarcinoma |
Tumor suppressor |
Inhibits inflammation and antitumor immunity |
Li et al., 2018; Yin et al., 2018
|
PRKN |
Colon cancer |
Tumor suppressor |
Inhibits cell proliferation |
Poulogiannis et al., 2010 |